Literature DB >> 12048353

Serum interleukin-18 concentrations in patients with inflammatory bowel disease.

Daisuke Furuya1, Atsuhito Yagihashi, Momoko Komatsu, Nakamura Masashi, Naoki Tsuji, Daisuke Kobayashi, Naoki Watanabe.   

Abstract

Elevated expression of interleukin (IL)-18 mRNA and protein in intestinal mucosa, attributable to activated monocytes and macrophages in that site, has been reported in patients with inflammatory bowel disease (IBD). However, changes in serum IL-18 concentrations in patients with IBD have not been reported. We measured bioactive IL-18 in serum from patients with IBD, using an enzyme-linked immunosorbent assay (ELISA). Mean serum IL-18 concentrations in 5 patients with Crohn disease (CD) were 400 pg/mL, approximately 1.7 times higher than concentrations in 21 control subjects (p < 0.01). However, serum IL-18 was not increased in patients with ulcerative colitis (UC). These results suggest that like other T-helper type 1 (Th1) cytokines IL-18 may play a key pathogenetic role in Th1-mediated disorders, such as CD. Regulation and expression of IL-18 appears to differ between CD and UC, and serum IL-18 may be a useful clinical marker for CD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12048353     DOI: 10.1097/00002371-200203001-00010

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  8 in total

1.  Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?

Authors:  Itta M Minderhoud; Melvin Samsom; Bas Oldenburg
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

2.  Plasma interleukin-18 reflects severity of ulcerative colitis.

Authors:  Alicja Wiercinska-Drapalo; Robert Flisiak; Jerzy Jaroszewicz; Danuta Prokopowicz
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

Review 3.  Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes.

Authors:  Altin Gjymishka; Roxana M Coman; Todd M Brusko; Sarah C Glover
Journal:  Immunotherapy       Date:  2013-12       Impact factor: 4.196

4.  Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models.

Authors:  P Maerten; C Shen; S Colpaert; Z Liu; D A M Bullens; G van Assche; F Penninckx; K Geboes; G Vanham; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

5.  Serum interleukin-1 receptor antagonist is an early indicator of colitis onset in Galphai2-deficient mice.

Authors:  O H Hultgren; M Berglund; M Bjursten; E Hultgren Hörnquist
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

6.  NLRP6 function in inflammatory monocytes reduces susceptibility to chemically induced intestinal injury.

Authors:  S S Seregin; N Golovchenko; B Schaf; J Chen; K A Eaton; G Y Chen
Journal:  Mucosal Immunol       Date:  2016-06-29       Impact factor: 7.313

Review 7.  Innate Lymphoid Cells in Intestinal Inflammation.

Authors:  Alessandra Geremia; Carolina V Arancibia-Cárcamo
Journal:  Front Immunol       Date:  2017-10-13       Impact factor: 7.561

Review 8.  Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.

Authors:  Stella Amarachi Ihim; Sharafudeen Dahiru Abubakar; Zeineb Zian; Takanori Sasaki; Mohammad Saffarioun; Shayan Maleknia; Gholamreza Azizi
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.